 |
|
Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
Seung Wook Hong, Jaewoo Park, Hyuk Yoon, Hye Ran Yang, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
Korean J Intern Med. 2021;36(Suppl 1):S9-S17. Published online 2020 Jun 25 DOI: https://doi.org/10.3904/kjim.2019.279
|
|
Citations to this article as recorded by
 Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease
Jasmijn Z. Jagt, Koen W. Holleman, Marc A. Benninga, Johan E. Van Limbergen, Nanne K. H. de Boer, Tim G. J. de Meij
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(1): 57. CrossRef The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
International Immunopharmacology.2024; 134: 112255. CrossRef Dopamine β-hydroxylase shapes intestinal inflammation through modulating T cell activation
Qiaoling Sun, Heng Li, Jing Lv, Weilin Shi, Yanfeng Bai, Ke Pan, Alice Chen
Cellular Immunology.2024; 401-402: 104839. CrossRef Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD
Sara Sila, Marina Aloi, Ugo Cucinotta, Laura Gianolio, Maya Granot, Ondrej Hradsky, Séamus Hussey, Ben Kang, Anna Karoliny, Kaija-Leena Kolho, Jan de Laffolie, Sara Lega, Manar Matar, Lorenzo Norsa, Sharon Omiwole, Esther Orlanski-Meyer, Laura Palomino, P
Inflammatory Bowel Diseases.2024;[Epub] CrossRef Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins
Kyeong Ok Kim, Si Hyung Lee
The Korean Journal of Gastroenterology.2024; 84(2): 43. CrossRef MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
Gregor Jezernik, Mario Gorenjak, Uroš Potočnik
Genes.2023; 14(2): 452. CrossRef Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang
World Journal of Gastroenterology.2023; 29(29): 4481. CrossRef Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
|